Eliezer Masliah

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3409363/publications.pdf

Version: 2024-02-01

116 papers 25,167 citations

52 h-index 20307 116 g-index

121 all docs

121 docs citations

times ranked

121

27665 citing authors

#	Article	IF	CITATIONS
1	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.4	5,861
2	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science, 2006, 314, 130-133.	6.0	5,422
3	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
4	Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13010-13015.	3.3	1,308
5	Direct Transfer of α-Synuclein from Neuron to Astroglia Causes Inflammatory Responses in Synucleinopathies. Journal of Biological Chemistry, 2010, 285, 9262-9272.	1.6	704
6	Neuron-released oligomeric $\hat{l}\pm$ -synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nature Communications, 2013, 4, 1562.	5 . 8	634
7	TGF- \hat{l}^21 promotes microglial amyloid- \hat{l}^2 clearance and reduces plaque burden in transgenic mice. Nature Medicine, 2001, 7, 612-618.	15.2	575
8	Genetic evidence for the involvement of ? in progressive supranuclear palsy. Annals of Neurology, 1997, 41, 277-281.	2.8	433
9	Amyloidogenic role of cytokine TGF- \hat{l}^21 in transgenic mice and in Alzheimer's disease. Nature, 1997, 389, 603-606.	13.7	408
10	Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nature Medicine, 2015, 21, 1154-1162.	15.2	398
11	Spectrum of human immunodeficiency virus-associated neocortical damage. Annals of Neurology, 1992, 32, 321-329.	2.8	365
12	Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission. Journal of Neuroscience, 2012, 32, 13454-13469.	1.7	290
13	Reducing C-Terminal-Truncated Alpha-Synuclein by Immunotherapy Attenuates Neurodegeneration and Propagation in Parkinson's Disease-Like Models. Journal of Neuroscience, 2014, 34, 9441-9454.	1.7	258
14	Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 63-72.	1.2	255
15	Nerve Growth Factor Gene Therapy. JAMA Neurology, 2015, 72, 1139.	4.5	240
16	Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nature Neuroscience, 2015, 18, 423-434.	7.1	221
17	Alphaâ€synuclein in Lewy Body Disease and Alzheimer's Disease. Brain Pathology, 1999, 9, 707-720.	2.1	217
18	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochemical Pharmacology, 2014, 88, 508-516.	2.0	196

#	Article	IF	CITATIONS
19	Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Experimental Neurology, 2012, 237, 318-334.	2.0	194
20	Metaâ€analysis of synaptic pathology in Alzheimer's disease reveals selective molecular vesicular machinery vulnerability. Alzheimer's and Dementia, 2016, 12, 633-644.	0.4	184
21	Glucocerebrosidase depletion enhances cell-to-cell transmission of α-synuclein. Nature Communications, 2014, 5, 4755.	5.8	157
22	Life Extension Factor Klotho Prevents Mortality and Enhances Cognition in hAPP Transgenic Mice. Journal of Neuroscience, 2015, 35, 2358-2371.	1.7	157
23	Parkinson's Disease Genes VPS35 and EIF4G1 Interact Genetically and Converge on α-Synuclein. Neuron, 2015, 85, 76-87.	3.8	149
24	DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. Nature Communications, 2015, 6, 8897.	5.8	143
25	Caspase Dependent DNA Fragmentation Might Be Associated with Excitotoxicity in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 1998, 57, 1041-1052.	0.9	134
26	The Role of Synaptic Proteins in the Pathogenesis of Disorders of the Central Nervous System. Brain Pathology, 1993, 3, 77-85.	2.1	133
27	Cellular senescence and Alzheimer disease: the egg and the chicken scenario. Nature Reviews Neuroscience, 2020, 21, 433-444.	4.9	132
28	A <i>de novo</i> compound targeting α-synuclein improves deficits in models of Parkinson's disease. Brain, 2016, 139, 3217-3236.	3.7	122
29	LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation. Nature Communications, 2018, 9, 3465.	5.8	121
30	Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating $\hat{l}\pm$ -synuclein transmission and neuroinflammation. Molecular Neurodegeneration, 2018, 13, 43.	4.4	117
31	Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies. , 2013, 138, 311-322.		115
32	Antagonizing Neuronal Toll-like Receptor 2 Prevents Synucleinopathy by Activating Autophagy. Cell Reports, 2015, 13, 771-782.	2.9	113
33	Exposure to bacterial endotoxin generates a distinct strain of \hat{l} ±-synuclein fibril. Scientific Reports, 2016, 6, 30891.	1.6	113
34	Mutant \hat{l}_{\pm} -synuclein exacerbates age-related decrease of neurogenesis. Neurobiology of Aging, 2008, 29, 913-925.	1.5	106
35	The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Scientific Reports, 2018, 8, 16165.	1.6	105
36	Expression of A152T human tau causes ageâ€dependent neuronal dysfunction and loss in transgenic mice. EMBO Reports, 2016, 17, 530-551.	2.0	103

#	Article	IF	CITATIONS
37	Accelerated epigenetic aging in brain is associated with pre-mortem HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2016, 22, 366-375.	1.0	101
38	Transgenic Models of αâ€Synuclein Pathology. Annals of the New York Academy of Sciences, 2003, 991, 171-188.	1.8	99
39	Role of $\hat{l}\pm$ -Synuclein in Adult Neurogenesis and Neuronal Maturation in the Dentate Gyrus. Journal of Neuroscience, 2012, 32, 16906-16916.	1.7	99
40	SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy. Journal of Neuroscience, 2018, 38, 3680-3688.	1.7	98
41	ESCRT-mediated Uptake and Degradation of Brain-targeted α-synuclein Single Chain Antibody Attenuates Neuronal Degeneration In Vivo. Molecular Therapy, 2014, 22, 1753-1767.	3.7	80
42	Non-cell-autonomous Neurotoxicity of $\hat{l}\pm$ -synuclein Through Microglial Toll-like Receptor 2. Experimental Neurobiology, 2016, 25, 113-119.	0.7	77
43	Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease. Neurobiology of Disease, 2016, 85, 206-217.	2.1	77
44	NitroSynapsin therapy for a mouse MEF2C haploinsufficiency model of human autism. Nature Communications, 2017, 8, 1488.	5.8	74
45	Differential effects of immunotherapy with antibodies targeting \hat{l}_{\pm} -synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiology of Disease, 2017, 104, 85-96.	2.1	72
46	Therapeutic advantage of pro-electrophilic drugs to activate the Nrf2/ARE pathway in Alzheimer's disease models. Cell Death and Disease, 2016, 7, e2499-e2499.	2.7	71
47	Glycogen synthase kinase 3 alteration in alzheimer disease is related to neurofibrillary tangle formation. Molecular and Chemical Neuropathology, 1996, 29, 253-261.	1.0	70
48	Preclinical development of a high affinity \hat{l}_{\pm} -synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \hat{l}_{\pm} -synuclein and attenuate \hat{l}_{\pm} -synuclein spreading in vivo. Neurobiology of Disease, 2019, 132, 104582.	2.1	68
49	\hat{l}_{\pm} -Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiology of Aging, 2014, 35, 2357-2368.	1.5	62
50	Neural Stem Cells Rescue Cognitive and Motor Dysfunction in a Transgenic Model of Dementia with Lewy Bodies through a BDNF-Dependent Mechanism. Stem Cell Reports, 2015, 5, 791-804.	2.3	58
51	Decreased Coenzyme Q10 Levels in Multiple System Atrophy Cerebellum. Journal of Neuropathology and Experimental Neurology, 2016, 75, 663-672.	0.9	57
52	Apathy and APOE4 are associated with Reduced BDNF Levels in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 1347-1355.	1.2	55
53	Fibroblast growth factor modulates HIV coreceptor CXCR4 expression by neural cells., 2000, 59, 671-679.		54
54	PPARÎ activation by bexarotene promotes neuroprotection by restoring bioenergetic and quality control homeostasis. Science Translational Medicine, 2017, 9, .	5.8	54

#	Article	lF	Citations
55	Differential Vulnerability of Calbindin-immunoreactive Neurons in HIV Encephalitis. Journal of Neuropathology and Experimental Neurology, 1995, 54, 350-357.	0.9	53
56	Parkinson Disease Mutant E46K Enhances α-Synuclein Phosphorylation in Mammalian Cell Lines, in Yeast, and in Vivo. Journal of Biological Chemistry, 2015, 290, 9412-9427.	1.6	52
57	ER-associated degradation regulates Alzheimer's amyloid pathology and memory function by modulating γ-secretase activity. Nature Communications, 2017, 8, 1472.	5.8	50
58	LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Science Translational Medicine, 2020, 12, .	5.8	49
59	Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders. Current HIV Research, 2015, 13, 43-54.	0.2	48
60	Systemic Central Nervous System (CNS)-targeted Delivery of Neuropeptide Y (NPY) Reduces Neurodegeneration and Increases Neural Precursor Cell Proliferation in a Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2016, 291, 1905-1920.	1.6	48
61	Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation. Neurobiology of Disease, 2017, 106, 222-234.	2.1	48
62	Noncanonical transnitrosylation network contributes to synapse loss in Alzheimer's disease. Science, 2021, 371, .	6.0	47
63	Protection from cyanideâ€induced brain injury by the Nrf2 transcriptional activator carnosic acid. Journal of Neurochemistry, 2015, 133, 898-908.	2.1	45
64	\hat{l}_{\pm} -Synuclein interferes with the ESCRT-III complex contributing to the pathogenesis of Lewy body disease. Human Molecular Genetics, 2016, 25, 1100-1115.	1.4	45
65	NitroSynapsin ameliorates hypersynchronous neural network activity in Alzheimer hiPSC models. Molecular Psychiatry, 2021, 26, 5751-5765.	4.1	43
66	The Amazon rain forest plant Uncaria tomentosa (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. Scientific Reports, 2019, 9, 561.	1.6	42
67	Patterns of Neurodegeneration in HIV Encephalitis. Journal of Neuro-AIDS, 1995, 1, 161-173.	0.2	41
68	Fetal Obstructive Uropathy: Patterns of Renal Pathology. Pediatric and Developmental Pathology, 2000, 3, 223-231.	0.5	40
69	Increased Tau Phosphorylation and Aggregation in the Hippocampus of Mice Overexpressing Corticotropin-Releasing Factor. Journal of Alzheimer's Disease, 2014, 43, 967-976.	1.2	40
70	Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. Molecular and Cellular Neurosciences, 2014, 62, 68-78.	1.0	40
71	LDL receptor-related protein (LRP) in Alzheimer's disease: Towards a unified theory of pathogenesis. Microscopy Research and Technique, 2000, 50, 268-272.	1.2	39
72	The Role of Synaptic Proteins in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2000, 924, 68-75.	1.8	36

#	Article	IF	Citations
73	Doublecortin expression in CD8+ Tâ€cells and microglia at sites of amyloidâ€Î² plaques: A potential role in shaping plaque pathology?. Alzheimer's and Dementia, 2018, 14, 1022-1037.	0.4	36
74	Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoproteinEâ€deficient mice. European Journal of Neuroscience, 2000, 12, 4541-4546.	1.2	35
75	SORLA attenuates EphA4 signaling and amyloid β–induced neurodegeneration. Journal of Experimental Medicine, 2017, 214, 3669-3685.	4.2	35
76	Early Selective Vulnerability of the CA2 Hippocampal Subfield in Primary Age-Related Tauopathy. Journal of Neuropathology and Experimental Neurology, 2021, 80, 102-111.	0.9	35
77	Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment. Free Radical Biology and Medicine, 2019, 141, 115-140.	1.3	34
78	An Anti- \hat{I}^2 -Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome. PLoS ONE, 2016, 11, e0152471.	1.1	33
79	Role of sulfiredoxin as a peroxiredoxin-2 denitrosylase in human iPSC-derived dopaminergic neurons. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E7564-E7571.	3.3	32
80	Systemic peptide mediated delivery of an siRNA targeting \hat{l} ±-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease. Neurobiology of Disease, 2019, 127, 163-177.	2.1	30
81	Transglutaminase 2 exacerbates αâ€synuclein toxicity in mice and yeast. FASEB Journal, 2014, 28, 4280-4291.	0.2	29
82	Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease. Journal of Neuroinflammation, 2015, 12, 236.	3.1	29
83	Distinct Pattern of Microgliosis in the Olfactory Bulb of Neurodegenerative Proteinopathies. Neural Plasticity, 2017, 2017, 1-15.	1.0	29
84	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	2.1	29
85	Locally reduced levels of acidic FGF lead to decreased expression of 28-kDa calbindin and contribute to the selective vulnerability of the neurons in the entorhinal cortex in Alzheimer's disease. Neuropathology, 2001, 21, 203-211.	0.7	28
86	Structural Diversity of Alzheimer's Disease Amyloid- \hat{l}^2 Dimers and Their Role in Oligomerization and Fibril Formation. Journal of Alzheimer's Disease, 2014, 39, 583-600.	1.2	26
87	Novel therapeutic strategy for neurodegeneration by blocking ${\sf A}\hat{\sf I}^2$ seeding mediated aggregation in models of Alzheimer's disease. Neurobiology of Disease, 2015, 74, 144-157.	2.1	26
88	Partial caudal duplication in a newborn associated with meningomyelocele and complex heart anomaly. Teratology, 2001, 63, 94-99.	1.8	25
89	Prion infection promotes extensive accumulation of α-synuclein in aged human α-synuclein transgenic mice. Prion, 2012, 6, 184-190.	0.9	24
90	Targeting Microglial and Neuronal Toll-like Receptor 2 in Synucleinopathies. Experimental Neurobiology, 2019, 28, 547-553.	0.7	24

#	Article	IF	Citations
91	Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson's Disease. Journal of Parkinson's Disease, 2015, 5, 669-680.	1.5	22
92	Abnormalities in Central Nervous System Development in Osteogenesis Imperfecta Type II. Pediatric and Developmental Pathology, 1999, 2, 124-130.	0.5	21
93	Effects of innate immune receptor stimulation on extracellular $\hat{l}\pm$ -synuclein uptake and degradation by brain resident cells. Experimental and Molecular Medicine, 2021, 53, 281-290.	3.2	21
94	Neurogranin binds α-synuclein in the human superior temporal cortex and interaction is decreased in Parkinson's disease. Brain Research, 2014, 1591, 102-110.	1.1	20
95	Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS. Experimental and Molecular Medicine, 2022, 54, 447-454.	3.2	19
96	Toward a unified therapeutics approach targeting putative amyloid- \hat{l}^2 oligomer receptors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13680-13681.	3.3	18
97	Effects of single and combined immunotherapy approach targeting amyloid β protein and αâ€synuclein in a dementia with Lewy bodies–like model. Alzheimer's and Dementia, 2019, 15, 1133-1148.	0.4	18
98	Altered expression of glutamate transporters under hypoxic conditions in vitro. Journal of Neuroscience Research, 2001, 64, 193-202.	1.3	17
99	The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies. Neurotherapeutics, 2020, 17, 1061-1074.	2.1	17
100	Increased BACE1 activity inhibits peripheral nerve regeneration after injury. Neurobiology of Disease, 2017, 106, 147-157.	2.1	16
101	Complex Vascular Lesions at Autopsy in a Patient With Phentermine-Fenfluramine Use and Rapidly Progressing Pulmonary Hypertension. Archives of Pathology and Laboratory Medicine, 1999, 123, 539-540.	1.2	15
102	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	1.5	13
103	Aggregates feel the strain. Nature, 2015, 522, 296-297.	13.7	12
104	Protein profiling of isolated uterine AA amyloidosis causing fetal death in goats. FASEB Journal, 2015, 29, 911-919.	0.2	12
105	Differential Effects of Pharmacologic and Genetic Modulation of NMDA Receptor Activity on HIV/gp120-Induced Neuronal Damage in an In Vivo Mouse Model. Journal of Molecular Neuroscience, 2016, 58, 59-65.	1.1	12
106	Perspective on the calcium dyshomeostasis hypothesis in the pathogenesis of selective neuronal degeneration in animal models of Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 183-185.	0.4	12
107	A neuropathologic diagnosis of Alzheimer's disease in an older adult with HIV-associated neurocognitive disorder. Neurocase, 2018, 24, 213-219.	0.2	12
108	Prodegenerative lκBα expression in oligodendroglial α-synuclein models of multiple system atrophy. Neurobiology of Disease, 2014, 63, 171-183.	2.1	10

#	Article	IF	CITATIONS
109	Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults. Journal of NeuroVirology, 2016, 22, 650-660.	1.0	9
110	Five and four dimensional experiments for robust backbone resonance assignment of large intrinsically disordered proteins: application to Tau3x protein. Journal of Biomolecular NMR, 2016, 65, 193-203.	1.6	9
111	Recognition memory span in autopsy-confirmed Dementia with Lewy Bodies and Alzheimer's Disease. Neuropsychologia, 2015, 75, 548-555.	0.7	8
112	MultiTEP platform–based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiology of Aging, 2017, 59, 156-170.	1.5	8
113	NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model. Neurobiology of Disease, 2019, 127, 390-397.	2.1	8
114	NPT520-34 improves neuropathology and motor deficits in a transgenic mouse model of Parkinson's disease. Brain, 2021, 144, 3692-3709.	3.7	8
115	Topographical distribution of synaptic-associated proteins in the neuritic plaques of Alzheimer's disease hippocampus. Acta Neuropathologica, 1994, 87, 135-142.	3.9	3
116	In Reply. Archives of Pathology and Laboratory Medicine, 2000, 124, 801-802.	1.2	2